Mereo BioPharma Group plc - ADR earnings per share and revenue
On Nov 10, 2025, MREO reported earnings of -0.01 USD per share (EPS) for Q3 25, beating the estimate of -0.02 USD, resulting in a 59.68% surprise. Revenue reached --, compared to an expected 11.90 million, with a -100.00% difference. The market reacted with a +5.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.01 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Mereo BioPharma Group plc - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Mereo BioPharma Group plc - ADR reported EPS of -$0.01, beating estimates by 59.68%, and revenue of $0.00, -100% below expectations.
How did the market react to Mereo BioPharma Group plc - ADR's Q3 2025 earnings?
The stock price moved up 5.65%, changed from $1.77 before the earnings release to $1.87 the day after.
When is Mereo BioPharma Group plc - ADR expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for Mereo BioPharma Group plc - ADR's next earnings report?
Based on 10
analysts, Mereo BioPharma Group plc - ADR is expected to report EPS of -$0.01 and revenue of -- for Q4 2025.